External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

India Financials / Thematic (Sector/Industry)

<ul><li>Max Healthcare Institute: EBITDA^ grew 23% YoY, with 21% YoY sales growth (hospital sales up 22% and Max Labs up 17%)</li><li>ARPOB grew 1% YoY (+3% growth in existing units), and occupancy was at 76% (vs 79% YoY)</li><li>Its expansion plan for the next 1-2 years is on track for both brownfield (commissioned 160 beds at Mohali in Q2, to commission 268 beds at Nanavati, Mumbai in mid-Nov 25, and Max Saket 400 beds by Dec 25) and greenfield (Gurgaon 501 in Q4FY26) beds, and margin should be steady for brownfield hospitals (cost synergies) for the next couple of years</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Max Healthcare Institute: EBITDA^ grew 23% YoY, with 21% YoY sales growth (hospital sales up 22% and Max Labs up 17%)ARPOB grew 1% YoY (+3% growth in existing units), and occupancy was at 76% (vs 79% YoY)Its expansion plan for the next 1-2 years is on track for both brownfield (commissioned 160 beds at Mohali in Q2, to commission 268 beds at Nanavati, Mumbai in mid-Nov 25, and Max Saket 400 beds by Dec 25) and greenfield (Gurgaon 501 in Q4FY26) beds, and margin should be steady for brownfield hospitals (cost synergies) for the next couple of yearsContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Max Healthcare Institute, Oil India, Ahluwalia Contracts, Ashoka Buildcon